TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05146154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin/Relebactam 1.25g
Description: Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin/Relebactam 1.25g
Description: Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.
Study: NCT06647849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: centers whose interns receive simulation training in the announcement of early spontaneous miscarriage between the 2 inclusion phases
Description: The simulation training sessions for the announcement consultation are set up directly in the centers participating in the with training arm of the study, after the first phase of patient inclusion. These sessions will take place in situ in the center's maternity ward, and will be run by a single team trained in simulation and announcement.~This team of trainers is identical for all centers randomized in the with training arm, and is made up of two trainers: an obstetrician-gynecologist and a psychologist.

Intervention type: OTHER
Group type: OTHER
Intervention: centers with standard in-house management of spontaneous miscarriage/pregnancy arrested in the emergency department
Description: In the participating centers included in the no training arm, interns will have no specific training in announcement. Patients will receive information concerning the diagnosis of a terminated pregnancy or miscarriage from interns not trained in simulation.~During the course of the study, training in the announcement of a miscarriage will be offered to interns from centers in the no training group.
Study: NCT06681974

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL:Information form with hygienic-dietary measures or sleep hygiene guidelines is provided and explained.
Description: * Establish a regular sleep schedule~* Do not stay in bed longer than our regular sleep schedule.~* Avoid naps during the day~* Do not perform exciting activities and/or activities that demand physical or mental energy in the 3 hours prior to going to bed.~* Avoid the use of mobile screens, as well as exposure to intense light in the 3 hours prior to going to bed.~* Follow a healthy bedtime routine~* Healthy lifestyle habits: avoid tobacco, alcohol and other toxic substances.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXPERIMENTAL: program of exercises that will be composed of 4 blocks
Description: the first is the work of the soft palate (retropalatine level), the second is the work of the functionality of the tongue (retroglossus level), the third is the work of the position of the hyoid bone (hypopharyngeal level), and the fourth is work on anterior head tilt and craniocervical extension (anterior head posture).
Study: NCT06683248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigate sleep deprivation
Description: Sleep deprivation~Devices used:~Dreem band for EEG Actiheart Tobii Eye tracker Blood glucose monitor Blood pressure cuff Mira fertility tracker Galvanic skin response K5: wearable metabolic system Fitbit: wearable technology Withings sleep analyzer Body composition monitor
Study: NCT06682598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent physical exercise training
Description: The subjects will perform one session per day of multicomponent physical exercise training, consisting of strength, power, balance, and walking exercises. The program will have progressive intensity and volume, adapted to the frailty level of the patient. The frailty level will be screened by the Short Physical Performance Battery. Each session will consist of two strength exercises for the upper limbs and one to three for the lower limbs. Also, one exercise for balance, and walking. Participants will be instructed to perform the concentric phase of the movement as fast as possible, since a good quality of movement is maintained, and the eccentric phase in two seconds. An expert researcher will supervise the entire session.
Study: NCT06687590

Intervention type: DEVICE
Intervention: Peripheral balloon angioplasty
Description: Serration balloon angioplasty of iliac, femoral, iliofemoral, popliteal, infrapopliteal and pedal arteries, or dysfunctional native or synthetic arteriovenous dialysis fistula
Study: NCT06689527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: Days 3 to 14: 6 mg/kg vamorolone once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Day 1 and 14: Single doses of 2.5 mg midazolam
Study: NCT06689176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irrisept® Antimicrobial Wound Lavage
Description: Irrisept® Antimicrobial Wound Lavage is a single-use, manual, self-contained irrigation device comprised of a 450mL bottle of 0.05% Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water for Irrigation, United States Pharmacopeia (USP) and an applicator (labeled Irriprobe®). The solution is aseptically filled in a Blow-Fill-Seal (BFS) bottle. The CHG acts as a preservative to inhibit microbial growth in the solution.
Study: NCT06686992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaccination
Description: The researcher will fill in the questionnaire and scales 5 minutes before the vaccination. During the procedure, the child will be played with roll-and-draw. The scales will be filled in again 5 minutes after the procedure. It will take an average of 5-10 minutes to fill out the forms.
Study: NCT06687733

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGGT002
Description: adeno-associated viral vector with human phenylalanine hydroxylase gene
Study: NCT05965479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan is an antibody-drug conjugate that contains trastuzumab covalently linked to deruxtecan, a topoisomerase I inhibitor. It is given by intravenous infusion.
Study: NCT05121545

Intervention type: RADIATION
Group type: OTHER
Intervention: Pro-GRID
Description: Study participants will receive a single treatment of Pro-GRID therapy. After which, the participants would be able to resume standard therapy (after one week) and receive additional radiotherapy one month after Pro-GRID therapy, if recommended. Participants will be in the study for one year. Follow-up appointments will be scheduled at 1, 3, 6 and 12 months posttreatment, and may include a history and physical exam, labs and/or a CT scan and toxicity assessments.
Study: NCT06330129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTT Pegasus
Description: The intervention aims to assess the construct validity of trunk flexor, extensor, and rotator muscle strength using the CTT PEGASUS isometric dynamometer (Leipzig, Germany). This involves correlating muscle strength measured isometrically with its physiological determinants: MRI-based anatomical cross-sectional area (CSA) in the lumbar region and muscle activation measured via surface electromyography (EMG) of spine and trunk muscles. Additionally, the intervention will assess the test-retest reliability of isometric strength of trunk flexors, extensors, and rotators.
Study: NCT05186428

Intervention type: OTHER
Group type: OTHER
Intervention: carrying out standard care
Description: The adaptation of the diuretic treatment will be made according to the possible diuresis records and the weighing of the patient every 2 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adult diaper
Description: the diuresis which will be calculated by making the difference between the weight of the soiled protection weighed and the weight of the dry protection
Study: NCT05109351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participating to Boost Meal Participation
Description: The Participating to Boost Meal Participation intervention consists of utilizing marketing and communication strategies to promote school meal participation in elementary school students.
Study: NCT06260761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIPO
Description: minimal invasive surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: standard surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT
Study: NCT06695429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Supplementation with 500 mL of beetroot juice daily in 2 doses of 250 mL, for 7 days, or until hospital discharge, and a recommendation to maintain a diet rich in vegetables with high nitrate content after discharge.
Study: NCT06686472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TL-925
Description: TL-925 is an eye drop.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Study: NCT06689072

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: To evaluate the role of repetitive Transcranial Magnetic Stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (DLPFC) in reducing pain, decreasing craving, alleviating withdrawal symptoms, lowering relapse rates, reducing impulsivity, and improving cognitive function in patients with Opioid Use Disorder

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psychotherapy
Description: Using psychotherapy in opioid use disorder.
Study: NCT06690177

Intervention type: DRUG
Group type: OTHER
Intervention: EscharEx (EX-03)
Description: a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EscharEx (EX-03)
Description: a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (Gel vehicle)
Description: A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Gel vehicle)
Description: A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
Study: NCT06687187

Intervention type: DRUG
Intervention: Neostigmine
Description: two groups (Group I, n= 41) and (Group II, n= 43) received varying doses of neostigmine (1 mg and 2 mg respectively

Intervention type: DRUG
Intervention: Neostigmine
Description: two groups (Group I, n= 41) and (Group II, n= 43) received varying doses of neostigmine (1 mg and 2 mg respectively
Study: NCT06689267

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: computed tomography myocardial perfusion
Description: The diagnostic value of CT perfusion (CTP) has been established in patients with stable coronary artery disease, but relevant studies have not yet been conducted in suspected NSTEMI patients. This study aims to explore the diagnostic and therapeutic value of an initial CTP strategy for suspected NSTEMI patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive Coronary Angiography
Description: Patients enrolled in the Invasive Coronary Angiography group will directly undergo coronary angiography. If necessary, intracoronary imaging (including IVUS and OCT) will be performed.
Study: NCT06685991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered intravenously at varying times during anesthesia induction to assess the impact of timing on postoperative outcomes. Participants will be randomized into one of three groups: one group will receive dexamethasone before the administration of fentanyl, a second group will receive it after the administration of a muscle relaxant, and a third control group will not receive dexamethasone. This timing variation aims to determine the optimal administration point to improve outcomes, including postoperative nausea, pain, glycemic stability, and hemodynamic response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered intravenously at varying times during anesthesia induction to assess the impact of timing on postoperative outcomes. Participants will be randomized into one of three groups: one group will receive dexamethasone before the administration of fentanyl, a second group will receive it after the administration of a muscle relaxant, and a third control group will not receive dexamethasone. This timing variation aims to determine the optimal administration point to improve outcomes, including postoperative nausea, pain, glycemic stability, and hemodynamic response.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered intravenously at varying times during anesthesia induction to assess the impact of timing on postoperative outcomes. Participants will be randomized into one of three groups: one group will receive dexamethasone before the administration of fentanyl, a second group will receive it after the administration of a muscle relaxant, and a third control group will not receive dexamethasone. This timing variation aims to determine the optimal administration point to improve outcomes, including postoperative nausea, pain, glycemic stability, and hemodynamic response.
Study: NCT06685900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital therapeutics
Description: Early intervention group will undergo app usage training, disease education, blood pressure measurements, orthostatic blood pressure measurements, and postprandial blood pressure measurements up to the third week of participation. From the fourth week onward, for a duration of 12 weeks, non-pharmacological treatment education will be provided through a digital therapeutic, and blood pressure will be measured according to a specified schedule.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital therapeutics
Description: Late intervention group will undergo app usage training, disease education, blood pressure measurements, orthostatic blood pressure measurements, and postprandial blood pressure measurements up to the ninth week of participation. From the tenth week onward, for a duration of 6 weeks, non-pharmacological treatment education will be provided through a digital therapeutic, and blood pressure will be measured according to a specified schedule.
Study: NCT06685822

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Eyelink Portable Duo
Description: Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their the lap of the caregiver and will face a computer monitor. After a sticker is applied to the forehead of the child and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
Study: NCT05868655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with Video-Based
Description: A program of stability and balance exercises will be provided

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standart exercise-Home-Based
Description: Participants will be asked to take the final measurements after the exercises have been monitored by a physical therapist for eight weeks.
Study: NCT06695234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Awareness Training
Description: A second-generation mindfulness-based intervention that reincorporates Buddhist wisdom concepts into mindfulness-based intervention.
Study: NCT06691243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: The initial dose will be semaglutide 0.25mg which, if tolerated, will be escalated to 0.5mg. Escalation will continue to 1.0 mg and afterwards to 2.0 mg. The highest possible dose will be 2.0mg semaglutide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to placebo arm will receive placebo injection every week.
Study: NCT06689488

Intervention type: DEVICE
Intervention: Ablation
Description: Bronchoscopy and microwave ablation prior to surgical resection.
Study: NCT06691568

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air purifier
Description: Purifiers were turned on for the active group and off for the placebo

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Air purifier
Description: Purifiers were turned on for the active group and off for the placebo
Study: NCT06686576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QL1706
Description: Phase Ib/Ⅲ： QL1706 will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPEOX
Description: Phase Ⅲ：CAPEOX will be administered
Study: NCT06687395

Intervention type: OTHER
Group type: OTHER
Intervention: Skill training on different models
Description: Skill training on different models (medium/high fidelity vs. self-made model)

Intervention type: OTHER
Group type: OTHER
Intervention: Skill training on different models
Description: Skill training on different models (medium/high fidelity vs. self-made model)
Study: NCT06686303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High frequency Segmental Vibrator
Description: Segmental vibrations of high frequency was used on each flexor and extensor interspersed with a 1 minute break.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined effects of high frequency segmental vibrator and neuromuscular electrical stimulation.
Description: Segmental vibrations of high frequency with Neuromuscular Electrical Stimulation was given on each flexor and extensor.
Study: NCT05691361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-324
Description: siRNA duplex oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-324
Description: siRNA duplex oligonucleotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline
Study: NCT05528445

Intervention type: DEVICE
Intervention: Neurosteer EEG recorder
Description: The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
Study: NCT04677153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test and treat plus peer mentors
Description: Rapid start of HCV treatment at OTP within days of HCV diagnosis. Participants will receive 8 weeks of glecaprevir/pibrentasvir and will work with a peer mentor during and after treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants are referred to another location for HCV treatment.
Study: NCT06470919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminders for upcoming vaccination(s)
Description: All parents/caregivers of children in participating villages will receive access to a digital vaccine card. This will be used for record-keeping application (digital vaccine registry). Selected parents/caregivers of children will receive SMS messages and reminders related to vaccination.
Study: NCT06340698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience intervention
Description: Contents of the first session include:~1. Resilience. Know the concept of resilience.~2. Stigma management. Discuss stigma experience and learn stigma management strategies such as normalizing the disease.~3. Self-efficacy. Learn ways of improving self-efficacy, such as experience of success and social support.~Contents of the second session include:~1. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions. Learn effective communication skills.~2. Acquiring social support. Know people and resources that could provide support when having HIV-related difficulties and mental health problems.~3. Emotional regulation. Understand the physiological responses to emotions. Know a range of emotional regulation strategies, such as cognitive reappraisal and deep breathing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence intervention
Description: Contents of the first session include:~1. Adherence behavioral skills. Identify barriers to optimal HAART adherence. Know behavioral skills that can deal with these barriers, such as forgetting, afraid of others' questioning and side effects.~2. Adherence information and motivation. Know how the HIV virus attack human body and the mechanisms of HAART medication. Understand the influence of adherence level on health outcomes.~Contents of the second session include:~1. Adherence motivation. Discuss possibilities and hope of future life, intimate relationship and career.~2. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions concerning HAART medication. Learn effective communication skills.~3. Acquiring social support. Know people and resources that could provide support when having HAART-related difficulties and problems.
Study: NCT06438250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-JH04
Description: The dose will be 148-222 MBq given intravenously.
Study: NCT06003790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-001
Description: Use of device 3 times per week for 8 weeks - for a total of 24 sessions.